EUVIMEDEUVIMED entdecken
LeitlinieÜbersichtsarbeit

Assessment of fitness for bleomycin use and management of bleomycin pulmonary toxicity in patients with classical Hodgkin lymphoma: A British Society for Haematology Good Practice Paper

Aisling Barrett iD, Nimish Shah iD, Andrew Chadwick, David Burns, Cathy Burton, David J Cutter, George A Follows, Pam McKay iD, Wendy Osborne, Elizabeth Phillips iD, Matthew R Wilson iD, Graham P Collins

British Journal of Haematology · 2025-01 · 206 (1) · 74-85

DOI: 10.1111/bjh.19840 ↗

Kurz gefasst

Leitlinie in der Zeitschrift British Journal of Haematology, online erschienen am 06.11.2024. Verfasst von Aisling Barrett und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematology, Oxford Cancer and Haematology Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK. Hauptthemen laut MEDLINE: Bleomycin, Hodgkin Disease, Lung Diseases, Antibiotics, Antineoplastic. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 109 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This good practice paper (GPP) is intended to support clinicians in assessing patient fitness for bleomycin and in management of bleomycin pulmonary toxicity (BPT) where it occurs. Bleomycin, originally developed as an antibiotic in the 1960s, has been a cornerstone of therapy for classical Hodgkin lymphoma (CHL) since results of its use in combination with doxorubicin, vincristine and dacarbazine (ABVD) were first published by Bonadonna et al in 1975 1. The same author recognised high rates of respiratory morbidity in these patients 2, and bleomycin‐;related pulmonary toxicity (BPT) is now a well‐;recognised and feared complication with its use. ABVD and BEACOPP/ BEACOPDac (bleomycin, cyclophosphamide, etoposide, doxorubicin, vincristine and prednisolone, with procarbazine or dacarbazine) are standard first‐;line treatments in CHL patients, but considerable variation remains in assessing patient fitness for bleomycin both clinically and with respiratory investigations. A recent survey of British haematologists regularly using bleomycin revealed that 87.5% have no local protocols for assessing patients in an evidence‐;based fashion, with wide variations in practice captured in the same survey (personal data). A working group was established and a literature review undertaken with the goal of presenting practical recommendations for clinicians regarding bleomycin use based on available evidence and expert opinion.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BleomycinHodgkin DiseaseLung DiseasesAntibiotics, AntineoplasticHumansAntineoplastic Combined Chemotherapy ProtocolsProcarbazineDoxorubicinDacarbazineVincristineEtoposideCyclophosphamideVinblastine

Stichwörter der Autor:innen

hodgkins lymphomalymphoid malignanciesmalignant lymphomas

Substanzen

BleomycinProcarbazineAntibiotics, AntineoplasticDoxorubicinDacarbazineVincristineEtoposideCyclophosphamideVinblastine

Autor:innen und Institutionen

  • Department of Haematology, Oxford Cancer and Haematology Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Medical Sciences Division, University of Oxford, Oxford, UK.
  • Department of Haematology, Norfolk and Norwich University Foundation Hospital, Norwich, UK.
  • Intensive Care Medicine and Anaesthesia, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Department of Haematology, University Hospitals Plymouth NHS Trust, Plymouth, UK.
  • Department of Haematology, The Leeds Teaching Hospitals NHS Trust, Leeds, UK.

ORCID-Profile: Aisling Barrett, Nimish Shah, Pam McKay, Elizabeth Phillips, Matthew R Wilson

Zitieren

APA

Barrett, A., Shah, N., Chadwick, A., Burns, D., Burton, C., Cutter, D. J., Follows, G. A., McKay, P., Osborne, W., Phillips, E., Wilson, M. R., & Collins, G. P. (2025). Assessment of fitness for bleomycin use and management of bleomycin pulmonary toxicity in patients with classical Hodgkin lymphoma: A British Society for Haematology Good Practice Paper. British Journal of Haematology, 206(1), 74-85. https://doi.org/10.1111/bjh.19840

Vancouver

Barrett A, Shah N, Chadwick A, Burns D, Burton C, Cutter DJ, et al. Assessment of fitness for bleomycin use and management of bleomycin pulmonary toxicity in patients with classical Hodgkin lymphoma: A British Society for Haematology Good Practice Paper. British Journal of Haematology. 2025;206(1):74-85. doi:10.1111/bjh.19840

BibTeX
@article{Barrett2025,
  author = {Barrett, Aisling and Shah, Nimish and Chadwick, Andrew and Burns, David and Burton, Cathy and Cutter, David J and Follows, George A and McKay, Pam and Osborne, Wendy and Phillips, Elizabeth and Wilson, Matthew R and Collins, Graham P},
  title = {Assessment of fitness for bleomycin use and management of bleomycin pulmonary toxicity in patients with classical Hodgkin lymphoma: A British Society for Haematology Good Practice Paper},
  journal = {British Journal of Haematology},
  year = {2025},
  volume = {206},
  number = {1},
  pages = {74--85},
  doi = {10.1111/bjh.19840}
}
Kostenlos starten →